newsfilter
← Latest News
PR Newswire·

Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List

UPPSALA, Sweden, Feb. 24, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This